SG11201900123TA - Compositions and methods for treating frontotemporal dementia - Google Patents

Compositions and methods for treating frontotemporal dementia

Info

Publication number
SG11201900123TA
SG11201900123TA SG11201900123TA SG11201900123TA SG11201900123TA SG 11201900123T A SG11201900123T A SG 11201900123TA SG 11201900123T A SG11201900123T A SG 11201900123TA SG 11201900123T A SG11201900123T A SG 11201900123TA SG 11201900123T A SG11201900123T A SG 11201900123TA
Authority
SG
Singapore
Prior art keywords
international
methods
compositions
seaport
ftd
Prior art date
Application number
SG11201900123TA
Inventor
Sethu Sankaranarayanan
Ted Yednock
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of SG11201900123TA publication Critical patent/SG11201900123TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111 11111111111111111 01011101H1111111111111111111111 0111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/017711 Al 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: A61K 39/395 (2006.01) GO1N 33/532 (2006.01) G01N 33/53 (2006.01) A61K 49/16 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: PCT/US2017/042846 (22) International Filing Date: 19 July 2017 (19.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/364,013 19 July 2016 (19.07.2016) US (71) Applicant: ANNEXON, INC. [US/US]; 180 Kimball Way, 2nd Floor, Suite 200, South San Francisco, CA 94080 (US). (72) Inventors: SANKARANARAYANAN, Sethu; 4720 Fal- _ staff Avenue, Fremont, CA 94555 (US). YEDNOCK, Ted; 184 Arroyo Road, Forest Knolls, CA 94333 (US). — = Agent: HALSTEAD, David, P. et al.; Foley Hoag (74) LLP, Seaport West, 155 Seaport Boulevard, Boston, MA = 02210-2600 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (81) _ CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = = = = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = — 1-1 ..! Declarations under Rule 4.17: ,_ 1 — of inventorship (Rule 4.17(iv)) 1-1 t , Published: N — with international search report (Art. 21(3)) 1-1 0 00 (54) Title: COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA 1-1 0 (57) : The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating frontotemporal ei dementia (FTD) or a variant of FTD, comprising administering to a subject an inhibitor of the complement pathway.
SG11201900123TA 2016-07-19 2017-07-19 Compositions and methods for treating frontotemporal dementia SG11201900123TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364013P 2016-07-19 2016-07-19
PCT/US2017/042846 WO2018017711A1 (en) 2016-07-19 2017-07-19 Compositions and methods for treating frontotemporal dementia

Publications (1)

Publication Number Publication Date
SG11201900123TA true SG11201900123TA (en) 2019-02-27

Family

ID=60992917

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900123TA SG11201900123TA (en) 2016-07-19 2017-07-19 Compositions and methods for treating frontotemporal dementia

Country Status (6)

Country Link
EP (1) EP3487531A4 (en)
AU (1) AU2017299579A1 (en)
CA (1) CA3030872A1 (en)
IL (1) IL264167A (en)
SG (1) SG11201900123TA (en)
WO (1) WO2018017711A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014287221C1 (en) 2013-07-09 2020-03-05 Annexon, Inc. Anti-complement factor C1q antibodies and uses thereof
JP6976943B2 (en) 2015-11-24 2021-12-08 アネクソン，インコーポレーテッド Anti-complement factor C1q Fab fragment and its use
CN108159421B (en) * 2018-02-05 2021-05-18 苏州大学 Application of phosphatidylserine blocking agent in preparation of medicine for treating diseases related to platelet quantity reduction
AU2019370485A1 (en) * 2018-11-02 2021-05-13 Annexon, Inc. Compositions and methods for treating brain injury
MX2023000949A (en) 2020-07-23 2023-02-22 Othair Prothena Ltd Anti-abeta antibodies.
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US9480658B2 (en) * 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
CN110818798A (en) * 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 Anti-complement C1s antibodies and uses thereof
AU2014287221C1 (en) * 2013-07-09 2020-03-05 Annexon, Inc. Anti-complement factor C1q antibodies and uses thereof
AU2015343029B2 (en) * 2014-11-05 2021-07-29 Annexon, Inc. Humanized anti-complement factor C1q antibodies and uses thereof

Also Published As

Publication number Publication date
EP3487531A1 (en) 2019-05-29
WO2018017711A1 (en) 2018-01-25
AU2017299579A1 (en) 2019-01-24
CA3030872A1 (en) 2018-01-25
IL264167A (en) 2019-02-28
EP3487531A4 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201811184UA (en) Lag -3 binding members
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201408261UA (en) Syringe
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201806853VA (en) Abstracted graphs from social relationship graph
SG11201805001UA (en) Method of treating influenza a
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201810765PA (en) Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
SG11201809813TA (en) Magnetic shield for medical devices
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same